COVID-19 Drug Associated APIs Global Market Report 2023 – By Drug Class (Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class), By Synthesis Type (Synthetic, Biotech), By Business Mode (Captive API, Merchant API) – Market Size, Trends, And Global Forecast 2023-2032

COVID-19 Rapid Test Kits Market Definition

The COVID-19 rapid test kits market consists of sales of COVID-19 rapid test kits and related services by entities (organizations, sole traders and partnerships) that offer kits aimed at the detection of COVID-19. COVID-19 rapid test kits are usually available as RT PCR test kits, rapid antigen test kits, or rapid antibody test kits and are manufactured by the entities that manufacture in-vitro rapid diagnostic tests in the medical equipment industry. The companies involved in manufacturing these rapid test kits are primarily engaged in the design, research and production of the rapid test kits which are used in hospitals and clinics, home care, diagnostic laboratories, and research institutions. COVID-19 is an infectious disease caused by the most recently discovered coronavirus. The most commonly used COVID-19 rapid tests are RT PCR and TrueNat PCR tests, which are primarily based on PCR, a procedure that repeatedly copies and amplifies the specific genetic fragments of the virus for detection. Other COVID-19 rapid test kits are an immunochromatography test designed for the qualitative presumptive detection of specific Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to SARS-CoV-2 in humoral fluid. These types of test kits require whole blood, serum, plasma, nasopharyngeal swab, oropharyngeal swab, or nasal swab as a sample to detect COVID-19 in humans; and are also suitable for point of care testing.

The COVID-19 rapid test kits are simple to use device that offer prompt results, typically in 20 minutes or less. The COVID-19 rapid test kits are either rapid antigen test kits or rapid antibody test kits manufactured by the entities that manufacture in-vitro rapid diagnostic tests in the medical equipment industry. The COVID-19 rapid test kits market covered in this report is segmented by test type into rapid antigen test, rapid antibody test, and others. The rapid antigen test kits are used to detect the antigens related to the COVID-19 virus. It is also segmented by kit type into equipment and extraction kits, and reagents and by specimen type into nasopharyngeal swab, oropharyngeal swab, nasal swab, blood sample, and others. The various end-users are hospitals and clinics, diagnostic laboratories, home care, and others. The global COVID-19 rapid test kits market is segmented - 1) By Test Type: Rapid Antigen Test, Rapid Antibody Test, Other Test Types 2) By Kit Type: Equipment and Extraction Kits, rRT-PCR Test Kits, Reagents 3) By Specimen Type: Nasopharyngeal swab, Oropharyngeal swab, Nasal swab, Other Specimen Types 4) By End-Users: Hospitals and Clinics, Diagnostic laboratories, Home Care, Other End-Users The global covid-19 rapid test kits market size grew from $6.57 billion in 2022 to $1.64 billion in 2023 at a compound annual growth rate (CAGR) of -75.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. Government regulations and steps to provide diversified diagnostic approaches are expected to boost the COVID-19 rapid test kits market growth during the forecast period. Better diagnostics facilities are required to overcome the increasing spread of COVID-19 cases globally, particularly in the rising geriatric population. In March 2020, the FDA has approved decentralized testing platforms to enlarge the testing capabilities across healthcare centres in the US. FDA issued a policy, under which, states can set up their platforms for authorizing the tests developed and the laboratories developing these tests need not engage with the FDA instead will engage with the respective state authorities. National Institutes of Health (NIH) has announced a Rapid Acceleration of Diagnostics (RADx), which is a fast track program for COVID-19 test development and distribution procedure under which it will be funding up to $500 million for the development of innovative SARS-CoV-2 diagnostic tests. Robust funding and investments by the public as well as private agencies for the rapid and innovative development of diagnostics for COVID-19 are expected to further boost the COVID-19 rapid test kits market. Major players in the COVID-19 rapid test kits market are Thermo Fisher Scientific, Abbott Laboratories, BioMedomics, CTK Biotech, F. Hoffmann-La Roche AG, Cepheid Inc., Cellex Inc., Acumen Research Laboratories, Biolidics, and LabCorp. Product recalls due to quality control issues are expected to hinder the market growth during the forecast period. Rapid medical device approval due to the present COVID-19 scenario paves the way to challenges such as product recalls due to safety, efficacy, and quality issues. In May 2020, Spartan Bioscience's rapid COVID-19 diagnostic kits which were approved with fast track designation April 2020 were recalled due to efficacy concerns posed by Health Canada regarding its proprietary swab. Health Canada paused the regulatory approval of the test kit and till then permitted the Spartan rapid test kit to be used for research purposes only. In April 2020, India recalled rapid-antibody testing kits imported from China due to efficacy issues, and all the procurement orders from China have also been canceled. The lack of proper screening and quality assurance along with fast track approval is expected to increase the product recalls which will hinder the COVID-19 rapid test kits market growth. The incorporation of Artificial Intelligence (AI) algorithms with the rapid diagnostic test kits are expected to boost market growth during the forecast period. In March 2020, Surgisphere announced the availability of a rapid diagnostic intelligent tool for COVID-19 that it developed to utilize three laboratory tests with a sensitivity of 93.7% and specificity of 99.9% to identify patients who are likely to be infected with Coronavirus. Surgisphere created a decision tree analysis to identify patients who are likely to be infected with Coronavirus, using clinical lab data of patients in the QuartzClinical platform which is a cloud-based healthcare data analytics platform. Early detection of patients results in faster treatment and thus saves more lives which can be achieved through the use of artificial intelligence along with the rapid diagnosis test. Companies in the COVID-19 rapid test kits market are focusing on integrating artificial intelligence (AI) in their test kits. AI algorithms help to integrate the findings of chest CT with clinical symptoms, exposure history, and laboratory testing to increase the chance of early detection of infection. For instance, in May 2021, US based public research university, the University of Utah in collaboration with US based nonprofit laboratory, ARUP laboratories and US based developer of AI software platforms for clinical pathology, Techcyte Inc. developed NanoSport.AI, a COVID-19 antibody test fueled by artificial intelligence. The test can quickly and easily detect whether individuals have some immunity against COVID-19 for travel or immigration purposes. In April 2020, Hememics Biotechnologies Inc., a US-based research and development company announced a partnership with Biomedical Research and Development Authority (BARDA) to develop a rapid antigen and antibody diagnostic tool which is Bluetooth-enabled. Under the partnership, BARDA will contribute $638,000 to Hememics for the manufacturing and scaling up production of the immune biosensor platform, which is a Bluetooth-enabled rapid diagnostic kit that screens people within 60 seconds with a single drop of blood or mucus. Biomedical Advanced Research and Development Authority (BARDA) is an office of US HHS, which takes measures against bioterrorism, epidemic, and pandemic diseases. North America was the largest region in the COVID-19 rapid test kits market in 2022. Western Europe was the second largest region in the global COVID-19 rapid test kits market share. The regions covered in the COVID-19 rapid test kits market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the COVID-19 rapid test kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The COVID-19 rapid test kits market consists of sales of molecular test kits and antigen test kits. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The COVID-19 rapid test kits market research report is one of a series of new reports from The Business Research Company that provides COVID-19 rapid test kits market statistics, including COVID-19 rapid test kits industry global market size, regional shares, competitors with a COVID-19 rapid test kits market share, detailed COVID-19 rapid test kits market segments, COVID-19 rapid test kits market trends and opportunities, and any further data you may need to thrive in the COVID-19 rapid test kits industry. This COVID-19 rapid test kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The COVID-19 detection test kits & consumables are used for the identification of novel coronavirus (SARS-CoV-2). This COVID-19 test kits & consumable uses a laboratory procedure called reverse transcription polymerase chain reaction to find the virus' genetic material (RT-PCR). The COVID-19 detection test kits and consumables market covered in this report is segmented by kits into viral load testing kits (qPCR and RT-PCR), virus-neutralizing assay kits, antibody detection kits (ELISA), viral antigen detection test kits, and others. It is also segmented by consumables into swabs, tubes, viral transfer media, reagents, and other consumables and by specimen type into nose and throat swab, blood, sputum, and nasal aspirate. The various end-uses of COVID-19 detection test kits and consumables are hospitals, clinics, public health labs, private and commercial labs, physicians labs, research institutes, and others. The global COVID-19 detection test kits and consumables market is segmented - 1) By Kits: Viral Load Testing Kits (qPCR and RT-PCR), Virus Neutralizing Assay Kits, Antibody Detection Kits (Elisa), Viral Antigen Detection Test Kits, Other Kits 2) By Consumables: Swabs, Tubes, Viral Transfer Media, Reagents, Other Consumables 3) By Specimen Type: Nose & Throat Swab, Blood, Sputum, Nasal Aspirate 4) By End Use: Hospitals, Clinics, Public Health Labs, Private And Commercial Labs, Physicians Labs, Research Institutes, Other End Uses The global covid-19 detection test kits and consumables market size grew from $6.7 billion in 2022 to $7.25 billion in 2023 at a compound annual growth rate (CAGR) of 8.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global covid-19 detection test kits and consumables is expected to grow from $9.83 billion in 2027 at a CAGR of 7.9%. The escalating demand for cost-effective and quick COVID-19 detection kits coupled with the easing of regulatory processes for COVID-19 detection kits contributed to the growth of the COVID-19 detection kits and consumables market. With the increasing incidence of COVID-19 (SARS-CoV-2) worldwide, the outbreak was declared as a Public Health Emergency of International Concern (PHEIC) by WHO. The WHO called for research on point of care diagnostics such as Rapid Diagnostic Tests (RTDs), which are small, simple stand-alone tests for use at the community level, and that can be carried out at the site of triage and outside the hospital, by minimally trained staff, round the clock, and on single samples, providing test results within 15 minutes. In the support of the research, regulatory bodies such as US FDA have eased the COVID-19 detection kits regulatory approval process allowing manufacturers to introduce COVID-19 detection kits in the market on a fast-track basis. Therefore, with the growing number of cases globally and the immense need for rapid diagnosis, the demand for cost-effective and quick COVID-19 detection kits is growing. This factor coupled with ease of the regulatory process for COVID-19 detection kits is driving the covid-19 detection test kits and consumables market. Major players in the COVID-19 detection test kits and consumables market are Cepheid, BGI, Abbott Laboratories, BioFire Diagnostics, F. Hoffmann-La Roche, GenMark Diagnostics, Mylab Discovery Solutions, Qiagen, Quidel Corporation, and Randox Laboratories. Huge demand to increase the capacity combined with a shortage of raw materials used in equipment and a reduced supply of particular reagents and consumables is expected to limit the growth of the COVID-19 detection test kits and consumables market. The pandemic outbreak resulted in lockdown all over the world which has brought shortages of raw materials and halted the supply chain of the particular reagents and consumables for the manufacturing companies as the countries depend on each other for it. For instance, Mpilo lab, the COVID-19 testing laboratory in Bulawayo has stopped conducting tests due to a critical shortage of consumables. Shortages of raw materials due to the disruption in the supply chain coupled with the high pressure to increase the production capacity to meet the demand is likely to harm the profit margins of the COVID-19 detection test kits and consumables market. CRISPR, a new diagnostic test for COVID-19 is based on CRISPR technology and can run on nasal swabs. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) based technologies are genomic editing technologies used for the exact detection of COVID-19 cases in an hour. The US FDA has granted Sherlock Biosciences an emergency use authorization (EUA) for the CRISPR test. The Sherlock Biosciences' CRISPR, therefore becomes the first FDA-authorized CRISPR technology on the market. Mammoth Biosciences is another company that is extensively working on this technology. In April 2020, Co-Diagnostics, a molecular diagnostics company has signed an agreement with Promega for additional manufacturing capacity for the urgent production of its Logix Smart COVID-19 test. Promega will support Co-Diagnostics with its innovative solutions and technical support by providing test kits of its new Logix Smart COVID-19 test to meet the demand during the pandemic. Logix Smart COVID-19 test uses the Co-Primer technology of Co-Diagnostics to target the RdRp gene of the SARS-CoV-2 virus that causes the disease. The test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments. Promega Corporation will begin supplying complete test kits for further distribution by Co-Diagnostics. The enhanced partnership enables Co-Diagnostics to reach additional testing facilities while leaning on Promega Corporation’s extensive manufacturing capabilities and increased capacity. North America was the largest region in the COVID-19 detection test kits and consumables market in 2022. The regions covered in the COVID-19 detection test kits and consumables market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the COVID-19 detection test kits and consumables market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The COVID-19 detection test kits & consumables market consists of sales of nucleic acid amplification tests (NAATs) and antigen tests. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The COVID-19 detection test kits and consumables market research report is one of a series of new reports from The Business Research Company that provides COVID-19 detection test kits and consumables market statistics, including COVID-19 detection test kits and consumables industry global market size, regional shares, competitors with a COVID-19 detection test kits and consumables market share, detailed COVID-19 detection test kits and consumables market segments, covid-19 detection test kits and consumables market trends and opportunities, and any further data you may need to thrive in the COVID-19 detection test kits and consumables industry. This COVID-19 detection test kits and consumables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric Vaccine Market Definition

The pediatric vaccine market consists of sales of pediatric vaccines and related services used to provide immunity to infants and children from birth to 18 years of age for specific diseases. Pediatric vaccines are a preparation of dead microorganisms, live attenuated organisms, or fully virulent organisms that are administered to stimulate the production of antibodies and provide immunity against one or several diseases among children. Pediatric vaccines are used in childhood immunization schedules to enhance a child’s immunity or prevent diseases such as diphtheria, tetanus, pertussis, influenza, Hepatitis B, polio, and many other infectious and non-infectious diseases. The market by value in this report is defined as the revenues that enterprises gain from goods and/or services within the specified market and geography. It does not include revenues from resales of goods and services such as media rights, and merchandise either further along the supply chain or as part of other products. Only goods and services traded between entities or sold to end consumers are included. Whether specifically stated or not, the markets for goods include related services and the markets for services include related goods.

DTP vaccines refer to a combination vaccine given intramuscularly to protect children under the age of 7 from diphtheria, tetanus, and whooping cough. It aids kids in acquiring resistance to the three bacterial illnesses, diphtheria, tetanus, and pertussis, which are all fatal. The main types of products in DTP vaccines are DTaP, TD, and Tdap. Diphtheria, tetanus, and whooping cough (DTaP) vaccines help children under the age of seven build protection against three lethal bacteria-borne diseases: diphtheria, tetanus, and whooping cough (pertussis). The different types of diseases include diphtheria, pertussis, and tetanus and involve various sectors such as hospitals, clinics, and vaccination centers. The global DTP vaccine market is segmented - 1) By Product Type: DTaP, TD, Tdap 2) By Disease: Diphtheria, Pertussis, Tetanus. 3) By End User: Hospitals, Clinics, Vaccination Centers The global DTP vaccines market size will grow from $6.02 billion in 2022 to $6.39 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the DTP vaccines is expected to grow from $7.79 billion in 2027 at a CAGR of 5.1%. Major players in the DTP vaccines market are Merck & Co., Sanofi, GSK, Lanzhou Institute of Biological Products, Novartis AG, Pfizer Inc., Johnson & Johnson, Seqirus, AJ Vaccines, and Bionet-Asia. Governments all over the world are encouraging the development of DTP vaccines in order to prevent the spread of the diseases. Countries such as India have the Universal Immunization Programme that aims to provide recommended vaccines against tuberculosis, polio, and other diseases including diphtheria, tetanus, and whooping cough for all Indian children. The country regularly conducts vaccination drives, which is expected to positively impact the growth of the market. These initiatives are expected to drive the DTP vaccines market growth in the forecast period. Inadequate vaccine access in developing countries is expected to limit the growth of the global DTP vaccine market. According to the World Health Organization’s global estimates, around 19.4 million infants did not have access to DTP vaccines, and around 60% of these children live in underdeveloped and developing countries. Countries such as the Central African Republic, Chad, Equatorial Guinea, Guinea, Samoa, Somalia, South Sudan, the Syrian Arab Republic, and Ukraine have less than 50% coverage of DTP vaccination. Lack of access to vaccines in underdeveloped countries is expected to hamper DTP vaccines market growth. Companies in the DTP vaccines market are increasingly investing in manufacturing DTP combination vaccines, which reduce the need for multiple vaccination shots for immunisation against infectious diseases. DTP combination vaccines such as tetravalent (DTP-HepB), pentavalent (DTP-HepB-Hib), and hexavalent (DTP-Hib-HepB-IPV) are available to provide the same protection as individual vaccine shots given separately. In May 2020, Merck acquired Thermis, a company focused on vaccines and immuno-modulation therapies for infectious diseases, for an undisclosed amount. Thermis is involved in the discovery, development, and production of vaccines with a sophisticated and versatile technology platform. Merck is expected to leverage the vaccine technology enhanced by Thermis, and the company will become a fully-owned subsidiary of Merck after the completion of this deal. North America was the largest region in the DTP vaccines market in 2022. The regions covered in the global DTP vaccine market analysis are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the DTP vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The DTP vaccine market consists of sales of Daptacel, Infanrix, Kinrix, Paediarix, Pentacel, Quadracel, and Vaxelis vaccines. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The DTP vaccines market research report is one of a series of new reports from The Business Research Company that provides DTP vaccines market statistics, including global market size, regional shares, competitors with a DTP vaccines market share, detailed DTP vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the DTP vaccines industry. This DTP vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biologics are medications made from organic materials that can be used to treat a wide range of illnesses, and they are frequently used to treat immune-related illnesses such Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The interesting aspect is that biologics are separated from various natural sources, whether they be carbohydrates, proteins, nucleic acids, or a complex mixture of these materials. The main types of biologics are monoclonal antibodies (MAbs), therapeutic proteins, and vaccines. Monoclonal antibodies, or mAbs, are created in a laboratory to combat a specific infection. The various route of administration includes oral, parenteral, and others that are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global biologics market is segmented - 1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribtuion Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Cancer MAbS, Immunological MAbS, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological MABS, Cardiovascular And Cerebrovascular MAbS, Other Monoclonal Antibodies (MAbs), Metabolic Disorders Therapeutic Proteins, Cancer Therapeutic Proteins, Cardiovascular Therapeutic Proteins, Immunological Therapeutic Proteins, Other Therapeutic Proteins, Anti-Infective Vaccines, Autoimmunity Vaccines, Other Vaccines The global biologics market size is expected to grow from $382.04 billion in 2022 to $416.65 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of global biologics market is expected to reach $599.62 billion in 2027 at a CAGR of 9.5%. Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early. Major companies in the biologics market include AbbVie, Johnson & Johnson, Amgen, Sanofi S.A, F. Hoffmann-La Roche Ltd., GlaxosmithKline, Novartis AG, Pfizer Inc., Teva Pharmaceuticals and CSL. The early generation of biologics is losing its patent protection and is expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase the competitiveness of the biologics market putting downward pressure on pricing and market value growth. The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure the safety, purity, and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER) or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) that specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products. North America was the largest region in the biologics market share in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global biologics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biologics market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The biologics market consists of sales of Tumor necrosis factor inhibitors, Interleukin inhibitors, B-cells inhibitors, and T-cells inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biologics market research report is one of a series of new reports from The Business Research Company that provides biologics market statistics, including biologics industry global market size, regional shares, competitors with a biologics market share, detailed biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the biologics industry. This biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Coronavirus (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19. The main types of drugs in coronavirus (COVID-19) current therapy are redeliver, hydroxychloroquine, ritonavir, lopinavir, interferon beta, and others. Remdesivir is an antiviral drug that works by preventing an RNA-based virus from replicating its viral genome within an infected cell. It was first used to combat the Ebola virus. It can be administered through various routes such as oral and intravenous. The different sectors include hospitals, clinics, and research institutes; others. The global coronavirus (COVID-19) current therapy market is segmented - 1) By Drug Type: Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, Other Drug Type 2) By Route Of Administration: Oral, Intravenous 3) By End User: Hospitals, Clinics, Research Institutes, and Other End Users The global coronavirus (covid-19) current therapy market size grew from $16.43 billion in 2022 to $11.73 billion in 2023 at a compound annual growth rate (CAGR) of -28.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global coronavirus (covid-19) current therapy market is expected to grow to $1.05 billion in 2027 at a CAGR of -45.3%. The outbreak of the pandemic COVID-19 contributed to the growth of the coronavirus (COVID-19) current therapy market. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a global pandemic. According to the World Health Organization (WHO), there were 10,719,946 cases of COVID-19, including 517,337 deaths reported to the WHO on July 3, 2020, and this number is expected to grow soon. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs, and drug manufacturers are ramping up production to meet the global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency programme initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible. Major players in the coronavirus (COVID-19) current therapy market report are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals. High costs involved in the research and development of therapeutic drugs and vaccines and the long waiting time required for each phase of clinical trials are expected to limit the growth of the coronavirus (COVID-19) current therapy market. According to a recent study published in the Journal of Health Economics by the Tufts Center for the Study of Drug Development, it is estimated to cost $2.6 billion in developing a new prescription medicine and gain marketing approval, and seven out of eight pipeline drugs will fail in the development process. Moreover, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an experimental drug to reach the market. High costs and long waiting times for drug development are expected to hamper the coronavirus (COVID-19) current therapy market growth. Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent plasma therapy (CP) is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to a patient with severe disease in order to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during a public health emergency. By 30th April 2020, around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients have enrolled, and 3,809 of them have undergone convalescent plasma transfusion. The experimental convalescent plasma therapy is likely to gain attention if enough data is supporting the results. In March 2020, Sanofi and Regeneron Pharmaceuticals planned to initiate clinical trials of the rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of COVID-19 symptoms. The US Food and Drug Administration (FDA) approved Kevzara to treat rheumatoid arthritis. The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg. North America is the largest region in the coronavirus (COVID-19) current therapy market in 2022. Middle East is expected to be the fastest growing region in the global coronavirus (COVID-19) current therapy market share during the forecast period. The regions covered in the coronavirus (COVID-19) current therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the coronavirus (COVID-19) current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The coronavirus (COVID-19) current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The coronavirus (COVID-19) current therapy market research report is one of a series of new reports from The Business Research Company that provides coronavirus (COVID-19) current therapy market statistics, including coronavirus (COVID-19) current therapy industry global market size, regional shares, competitors with a coronavirus (COVID-19) current therapy market share, detailed coronavirus (COVID-19) current therapy market segments, coronavirus (COVID-19) current therapy market trends and opportunities, and any further data you may need to thrive in the coronavirus (COVID-19) current therapy industry. This coronavirus (COVID-19) current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Hydroxychloroquine refers to a quinolone-derived medication that is used to treat malaria. In countries or regions where it is recognised that other medications (such chloroquine) may not be effective, it is also used to prevent malaria infection. In some hospitalised individuals, hydroxychloroquine may also be used to treat coronavirus (COVID-19). The main types of drug activities in hydroxychloroquine are anti-malarial, anti-rheumatic, lupus suppressant, anti-COVID-19, and others. Antimalarial drugs, or simply "antimalarials," are antiparasitic chemical agents that can be utilised to cure or prevent malaria. They are generally organically sourced. The different formulations include tablets, and injections and are used in malaria, rheumatoid arthritis, lupus erythematosus, COVID-19, and others. It is distributed through various channels such as hospital pharmacies, online pharmacies, specialty drug stores, and retail pharmacies. The global hydroxychloroquine market is segmented - 1) By Drug Activity: Anti-Malarial Drug, Anti-Rheumatic Drug, Lupus Suppressant Drug, Anti COVID-19 Drug, Other Drug Activity 2) By Formulation: Tablets, Injection 3) By Application: Malaria, Rheumatoid Arthritis, Lupus Erythematosus, COVID-19, Other Applications 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Speciality Drug Stores, Retail Pharmacy The global hydroxychloroquine market size grew from $1.8 billion in 2022 to $1.93 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global hydroxychloroquine is expected to grow from $2.52 billion in 2027 at a CAGR of 6.9%. The increasing number of coronavirus cases has increased the demand for hydroxychloroquine market in 2020. The demand for hydroxychloroquine is growing attributing to its use in the treatment of COVID-19 patients and the ongoing clinical trials. The US Food and Drug Administration has authorized the emergency use of hydroxychloroquine for the treatment of COVID-19 patients in the hospital or enrolled in clinical trials. According to the World Health Organization (WHO), there were more than 10 million confirmed cases of COVID-19, including more than 500,000 deaths reported as of 3rd July 2020, globally. USA, Brazil, Russia, UK, India, and Spain are the countries most affected by the virus. Therefore, the continuous increase in coronavirus cases across the globe is surging the demand for hydroxychloroquine, generating higher revenues for the hydroxychloroquine market during the period. Major players in the hydroxychloroquine market are Bayer AG, Dr. Reddy's Laboratories, Zydus Cadila, Ipca Laboratories Ltd., Wallace Pharma, Teva, Mylan, Novartis, and Intas Pharmaceuticals. Side effects associated with the use of hydroxychloroquine market drugs are predicted to limit market growth. The side effects associated with the use of hydroxychloroquine for the treatment of COVID patients include serious and potentially life-threatening heart rhythm problems. In April 2020, the US Food and Drug Administration warned against the side effects of hydroxychloroquine and issued a safety communication regarding the side effects of using the drug for COVID-19 outside of hospital settings or clinical trials. Moreover, the World Health Organization (WHO) suspended the clinical trials of hydroxychloroquine over safety concerns on the 25th of May 2020. However, the trials have been resumed by WHO on the 3rd of June 2020 after reviewing safety concerns. Nonetheless, the potential side effects restrict the use of hydroxychloroquine outside the hospital and clinical settings, thereby hindering the growth of the hydroxychloroquine market going forward. Major players operating in the market are undertaking various strategic initiatives such as increasing production capacity and the expansion of manufacturing plants to meet the augmented global demand. For instance, in April 2020, Zydus Cadila announced that the company has ramped up its production capacity by 10 times for the production of hydroxychloroquine post the COVID-19 outbreak. Moreover, other manufacturers including IPCA Laboratories increased their monthly hydroxychloroquine production capacity five to six times during May 2020. Thus, the ramp-up of production capacities by major companies is a major trend shaping the hydroxychloroquine market. In March 2020, Rising Pharma Holdings, Inc., a US-based pharmaceutical company, and Lauras Labs Ltd., an India-based pharmaceutical and biotechnology company, entered into a collaboration agreement on a clinical trial exploring the use of hydroxychloroquine as a preventive treatment for coronavirus illness with the Department of Infectious Disease at the University of Minnesota (COVID-19). Hydroxychloroquine is a medicine for rheumatoid arthritis, lupus, and porphyria cutanea tarda, as well as for the prevention and treatment of some forms of malaria. The University of Minnesota is a US-based public research university pioneering research programs for undergraduates and graduates. North America is the largest region in the hydroxychloroquine market in 2022. Middle East is expected to be the fastest-growing region in the hydroxychloroquine market report. The regions covered in the hydroxychloroquine industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hydroxychloroquine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hydroxychloroquine market consists of sales of plaquenil, antimalarials, and immunosuppressants. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the chain, either further along the supply chain or as part of other products. The hydroxychloroquine market research report is one of a series of new reports from The Business Research Company that provides hydroxychloroquine market statistics, including hydroxychloroquine industry global market size, regional shares, competitors with a hydroxychloroquine market share, detailed hydroxychloroquine market segments, market trends and opportunities, and any further data you may need to thrive in the hydroxychloroquine industry. This hydroxychloroquine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.